Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are there any dots to connect with Friday's news and the fact that Missling did not dilute at all last quarter?
What's your opinion on why Missling has not raised any money (sold shares) for the past 3 months?
This is a particularly good question, considering the stock was over $6 a few months ago. Wish I had the answer. I can guess though.....
Tootall, any predictions on price targets in near term and long term?
600,000 shares traded in the first 10 minutes.
I'm getting spoiled. Stock is up 16% and I'm like, dammit we didn't hold $6!
Any reason to get excited about the pre-market or just a head fake?:
Anavex Life Sciences Corp (AVXL:NASDAQ)
Export chart+ WATCHLIST
Real Time Quote | Last NASDAQ LS, VOL From CTA | USD
Extended Hours | 8:44:18 AM EST
Volume
5.35 + 0.38 (+7.65%)
7,754
https://www.benzinga.com/news/earnings/20/02/15326684/4-momentum-stocks-to-watch
Just short of 5 bucks and 3 million shares traded. With the market closed on Monday, things could get interesting tomorrow. Would be a nice time for Dr. Missling to drop a pr bomb.
Don't recall Bishop calling in to any of the recent conference calls. Hopefully a positive sign. Maybe he puts out another good note in the next few days, perhaps even tomorrow.
Anybody know what the average time frame is from fast track designation to approval?
Bishop is really going all-in on AVXL. First his newsletter and now Forbes.
Andy Biotech
?
@AndyBiotech
24m24 minutes ago
$BIIB #CTAD19 FDA will look at every application through risk/benefit analysis.
Is the minuscule effect size really worth the side effect here for high dose aducanumab?
34% ARIA-E
19% ARIA-H, microhemorrhage
14% ARIA-H, superficial siderosis
8% Symptomatic ARIA
Allison DeAngelis
?
@BosBizAllison
12m12 minutes ago
So far, here's the @biogen aducanumab tl;dr: the drug appears to make a difference in amyloid plaque levels, but shows marginal effect in cognition, memory, etc.
Here's a quick, bottom line video from the Wall Street Journal on what BIIB's announcement actually means:
Investors were shocked to learn that Biogen now plans to pursue regulatory approval for the experimental Alzheimer’s disease drug they previously pulled the plug on. But @CGrantWSJ explains why the optimism may be premature. #WSJWhatsNow https://t.co/QVXRmJs4NP pic.twitter.com/U6UmWUP8Le
— The Wall Street Journal (@WSJ) October 22, 2019
Tweet from Max Nisen, healthcare columnist at Bloomberg:
@MaxNisen
4h4 hours ago
I'll be absolutely shocked if this works. Post-hoc subset analysis of this type is bad scientific practice and unreliable, generally speaking. It's hypothesis generating. If you interrogate any dataset enough, you can generate a positive result.
Interesting tweet from Rebecca Spalding, a M&A reporter at Reuters:
@rcurtisspalding
Mike Ehlers, Biogen's former head of R&D, left at the beginning of this month.
Just putting that out there.
9:34 AM - 22 Oct 2019
Let's say the good Dr. is currently in negotiations with both Eisai and Merck to partner on Alzheimer's. What do we realistically want the deal to look like? Money, stock, percentage of the pie, FDA approval contingencies, etc.?
I guess anything is possible, but my guess is a press release is embargoed until presentation time at 11:45am ET.
AAIC is less than two weeks away. Can't imagine they would do this now, with all big pharma eyes on us, if it was for a negative reason. Guessing something good is coming.
Preferred shares:
https://en.wikipedia.org/wiki/Preferred_stock
Occasionally companies use preferred shares as means of preventing hostile takeovers, creating preferred shares with a poison pill (or forced-exchange or conversion features) which are exercised upon a change in control. Some corporations contain provisions in their charters authorizing the issuance of preferred stock whose terms and conditions may be determined by the board of directors when issued. These "blank checks" are often used as a takeover defense; they may be assigned very high liquidation value (which must be redeemed in the event of a change of control), or may have great super-voting powers.
BIIB down another $3.50.
Woof. That dog has fleas.
Anybody have a link to the Roth video? Can't seem to find it.
Just got a robocall from Dr. Missling about voting. You can vote online at this link once you receive your voting instructions:
https://www.aalvote.com/avxl
By your top estimate, my investment is worth $2.7 billion. Not bad.
Yes, taking all with a grain of salt, but always fun to speculate. Now I'm going to buy 12 houses this weekend.
Forget the naysayers. Post that spreadsheet!
BIIB closes down again, $9 drop. Ooooff.
Tweet from the Chairman, Dept of Psychiatry, Columbia University and Director, New York State Psychiatric Institute:
Jeffrey A. Lieberman
@DrJlieberman
9h9 hours ago
After reviewing report from Biogen and talking to some colleagues I’m skeptical. While people’s hopes and company’s stock price may go up because of company’s enthusiastic report echoed by the #media the chances of a breakthrough drug have not.
https://twitter.com/DrJlieberman
BIIB down another $4.34
Financial Times
Biogen Shares Fall On Alzheimer's Trial Results
David Crow-21 MINUTES AGO
Shares in Biogen fell by almost 10 per cent in after-hours trading as investors poked holes in a trial of an Alzheimer’s medicine that the company had billed as a success.
Investors were unnerved by the fact that patients on lower doses of the drug — which is being developed in conjunction with Japan’s Eisai — declined more quickly than those who received a placebo.
The finding — which was not shared with reporters at an earlier embargoed briefing — appeared to cast uncertainty on the finding that higher doses of the drug could slow the rate at which patients declined.
https://www.ft.com/content/486c67c4-904f-11e8-bb8f-a6a2f7bca546
BIIB getting crushed in AH trading. Down $46.
If A2-73 works for 80% of patients, imagine what A3-71 can do.
BIIB doesn't have this guy, we do. Our ace in the hole, Ern Heaven:
BIIB down $9 today.
Yes Bio, would like to hear your valuation.
Thanks!
Keep hitting a wall at $4.35. Break through that and we goin' Sizzler.
Interesting quote from billionaire Ron Baron about his investment in Tesla, which kind of reminds me of my investment in AVXL:
"You have to expect when you're doing something entirely different than what anyone has done before, not everything is going to happen on time."
Still find it interesting that MS has disappeared from the presentation.
I don't think there is a webcast for this 9am Alzheimer's panel. I think there's only a webcast of Anavex's corporate presentation later today.
Jesse Jackson just revealed earlier today that he has Parkinson's.
Very confusing. They cut MS from Slide 4, but still have Wayne State/Biogen listed for MS on the indications Slide 36.
The plot thickens.....